Cargando…

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma

INTRODUCTION: Gene amplification is an important mechanism for activating oncogenes in malignant tumors. Although amplification of HER2, C-MYC, CCND1 and FGFR1 has been reported in breast cancers, their role in the progression of in situ to invasive breast carcinoma is unclear. To investigate this q...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Min Hye, Kim, Eun Joo, Choi, Yoomi, Lee, Hee Eun, Kim, Yu Jung, Kim, Jee Hyun, Kang, Eunyoung, Kim, Sung-Won, Kim, In Ah, Park, So Yeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680930/
https://www.ncbi.nlm.nih.gov/pubmed/22863309
http://dx.doi.org/10.1186/bcr3239
_version_ 1782273179064991744
author Jang, Min Hye
Kim, Eun Joo
Choi, Yoomi
Lee, Hee Eun
Kim, Yu Jung
Kim, Jee Hyun
Kang, Eunyoung
Kim, Sung-Won
Kim, In Ah
Park, So Yeon
author_facet Jang, Min Hye
Kim, Eun Joo
Choi, Yoomi
Lee, Hee Eun
Kim, Yu Jung
Kim, Jee Hyun
Kang, Eunyoung
Kim, Sung-Won
Kim, In Ah
Park, So Yeon
author_sort Jang, Min Hye
collection PubMed
description INTRODUCTION: Gene amplification is an important mechanism for activating oncogenes in malignant tumors. Although amplification of HER2, C-MYC, CCND1 and FGFR1 has been reported in breast cancers, their role in the progression of in situ to invasive breast carcinoma is unclear. To investigate this question we compared the amplification frequencies of these genes in pure ductal carcinoma in situ (DCIS), DCIS associated with invasive carcinoma, and invasive carcinoma. METHODS: We performed fluorescence in situ hybridization of the selected genes on tissue microarrays composed of 179 pure DCIS and 438 invasive carcinomas. Two hundred and sixteen of the latter had DCIS components, and in those cases we compared gene amplification in the intraductal and invasive components of each carcinoma. RESULTS: The rate of amplification of FGFR1 was higher in invasive carcinomas than in the pure DCIS, but the opposite was true for HER2 amplification. These findings applied consistently to high-grade tumors, but not to low/intermediate-grade tumors. The amplification status of HER2, C-MYC, CCND1 and FGFR1 was generally similar in the matched invasive and DCIS components of the same tumors. However, FGFR1 amplification was more common in the invasive components than in the DCIS components. In survival analyses, FGFR1 amplification was found to be an independent prognostic factor for poor disease-free survival for all patients with invasive carcinoma and for the hormone receptor-positive subgroup. CONCLUSION: Amplification of HER2, C-MYC and CCND1 seems to play a role in the early development of breast cancer, but not in its progression. However, the increased frequency of FGFR1 amplification in invasive carcinomas compared with pure DCIS and in the invasive components of individual tumors, and its association with decreased disease-free survival, suggests a role for FGFR1 amplification in the progression of breast cancer including in situ-to-invasive transition, as well as initiation.
format Online
Article
Text
id pubmed-3680930
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36809302013-06-25 FGFR1 is amplified during the progression of in situ to invasive breast carcinoma Jang, Min Hye Kim, Eun Joo Choi, Yoomi Lee, Hee Eun Kim, Yu Jung Kim, Jee Hyun Kang, Eunyoung Kim, Sung-Won Kim, In Ah Park, So Yeon Breast Cancer Res Research Article INTRODUCTION: Gene amplification is an important mechanism for activating oncogenes in malignant tumors. Although amplification of HER2, C-MYC, CCND1 and FGFR1 has been reported in breast cancers, their role in the progression of in situ to invasive breast carcinoma is unclear. To investigate this question we compared the amplification frequencies of these genes in pure ductal carcinoma in situ (DCIS), DCIS associated with invasive carcinoma, and invasive carcinoma. METHODS: We performed fluorescence in situ hybridization of the selected genes on tissue microarrays composed of 179 pure DCIS and 438 invasive carcinomas. Two hundred and sixteen of the latter had DCIS components, and in those cases we compared gene amplification in the intraductal and invasive components of each carcinoma. RESULTS: The rate of amplification of FGFR1 was higher in invasive carcinomas than in the pure DCIS, but the opposite was true for HER2 amplification. These findings applied consistently to high-grade tumors, but not to low/intermediate-grade tumors. The amplification status of HER2, C-MYC, CCND1 and FGFR1 was generally similar in the matched invasive and DCIS components of the same tumors. However, FGFR1 amplification was more common in the invasive components than in the DCIS components. In survival analyses, FGFR1 amplification was found to be an independent prognostic factor for poor disease-free survival for all patients with invasive carcinoma and for the hormone receptor-positive subgroup. CONCLUSION: Amplification of HER2, C-MYC and CCND1 seems to play a role in the early development of breast cancer, but not in its progression. However, the increased frequency of FGFR1 amplification in invasive carcinomas compared with pure DCIS and in the invasive components of individual tumors, and its association with decreased disease-free survival, suggests a role for FGFR1 amplification in the progression of breast cancer including in situ-to-invasive transition, as well as initiation. BioMed Central 2012 2012-08-03 /pmc/articles/PMC3680930/ /pubmed/22863309 http://dx.doi.org/10.1186/bcr3239 Text en Copyright ©2012 Jang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jang, Min Hye
Kim, Eun Joo
Choi, Yoomi
Lee, Hee Eun
Kim, Yu Jung
Kim, Jee Hyun
Kang, Eunyoung
Kim, Sung-Won
Kim, In Ah
Park, So Yeon
FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
title FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
title_full FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
title_fullStr FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
title_full_unstemmed FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
title_short FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
title_sort fgfr1 is amplified during the progression of in situ to invasive breast carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680930/
https://www.ncbi.nlm.nih.gov/pubmed/22863309
http://dx.doi.org/10.1186/bcr3239
work_keys_str_mv AT jangminhye fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT kimeunjoo fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT choiyoomi fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT leeheeeun fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT kimyujung fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT kimjeehyun fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT kangeunyoung fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT kimsungwon fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT kiminah fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma
AT parksoyeon fgfr1isamplifiedduringtheprogressionofinsitutoinvasivebreastcarcinoma